Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Fujifilm to Take Majority Stake in Regenerative Medicine Startup J-TEC
November 4, 2014
- Bayer Seeks New Indications for Antibiotic Ciproxan
November 4, 2014
- AnGes MG to Initiate Multinational PIII Study of Collategene in Europe
November 4, 2014
- Takeda Aims for Consecutive Sales Growth through FY2022
October 31, 2014
- Sumitomo Dainippon’s Sales Down 1.7% on Drug Price Cuts in Japan
October 31, 2014
- Eisai Flounders in Japan, US Markets, Half-Year Profits Dive 60%
October 31, 2014
- Takeda Reports 2.8% Rise in First-Half Sales
October 31, 2014
- MTPC Files Remicade for Behcet’s Disease with Special Lesions
October 31, 2014
- Smaller Crestor Royalties Send Shionogi’s April-Sept. Sales Lower
October 30, 2014
- MTPC’s Half-Year Sales Dip, but Operating Profit Jumps on Gilenya Royalties
October 30, 2014
- Chugai to Supply Tamiflu for 7 Million Persons This Flu Season
October 30, 2014
- GPCR Consortium, an International Partnership of Industry and Academia, Established: Ono
October 30, 2014
- Safety of Lorcaserin Confirmed in Concomitant Administration with Phentermine: Eisai
October 30, 2014
- Fujifilm to Buy US Vaccine CMO
October 29, 2014
- Mario Stein Named as New President of J&J Consumer Company
October 29, 2014
- Bristol’s Involvement in Sprycel Trial Could Contravene Ethics Code, but Not PAL: Probe
October 28, 2014
- US Judge Cuts Damages Takeda to Pay over Actos from US$6 Billion to US$27.65 Million
October 28, 2014
- GSK Files Lamictal Monotherapy for Typical Absence Seizures in Pediatric Patients
October 28, 2014
- NBI Files Spiriva-LABA Combination Drug for Approval
October 28, 2014
- 3 Major Wholesalers Acknowledge Illegal Diversion of Ethical Drugs to Wholesalers
October 28, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…